AIDS and Behavior

, Volume 17, Issue 7, pp 2490–2500 | Cite as

HIV Among Injection Drug Users and Their Intimate Partners in Almaty, Kazakhstan

  • Nabila El-Bassel
  • Louisa Gilbert
  • Assel Terlikbayeva
  • Elwin Wu
  • Chris Beyrer
  • Stacey Shaw
  • Tim Hunt
  • Xin Ma
  • Mingway Chang
  • Leyla Ismayilova
  • Marat Tukeyev
  • Baurzhan Zhussupov
  • Yelena Rozental
Original Paper

Abstract

This paper examines prevalence rates of HIV, HCV, and syphilis among a sample of injecting drug users (IDUs) and their heterosexual intimate partners (N = 728) from Almaty, Kazakhstan. The study uses baseline data from Project Renaissance, a couple-based HIV prevention intervention delivered to a couple where one or both partners are IDUs. HIV prevalence rates among female and male IDUs were 28 %. Among the full sample, 75 % had HCV, and 13 % tested positive for the syphilis antibody test. Only 10 % of the sample ever visited a needle exchange program. One-fourth (25.3 %) had never been tested for HIV. One-quarter of those who tested positive were unaware of their status. Being HIV positive was associated with a history of incarceration, being an IDU, and having access to needle exchange programs. The findings call for increasing efforts to improve access to HIV testing, prevention, treatment, and care for IDUs in Almaty, Kazakhstan.

Keywords

Injecting drug use HIV Central Asia 

References

  1. 1.
    Aceijas CC, Friedman SR, Cooper HLF, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect. 2006;82(suppl_3).Google Scholar
  2. 2.
    RAC. HIV surveillance update for Kazakhstan by oblast and risk group. Unpublished Ministry of Health statistics. 2011.Google Scholar
  3. 3.
    UNAIDS. Report on the global AIDS epidemic. 2010.Google Scholar
  4. 4.
    Deryabina A, Krukova V, Gwynn S. Zhussupov B. McFarland W: Report on the evaluation of HIV integrated biobehavioral surveillance in the Republic of Kazakhstan; 2012.Google Scholar
  5. 5.
    UNAIDS. Together we will end AIDS. 2012.Google Scholar
  6. 6.
    Beyrer C, Patel Z, Stachowiak JA, et al. Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe Tajikistan. AIDS Res Hum Retrovirus. 2009;25(9):853–60.CrossRefGoogle Scholar
  7. 7.
    Thorne C, Ferencic N, Malyuta R, Mimica J, Niemiec T. Central Asia: hotspot in the worldwide HIV epidemic. Lancet Infect Dis. 2010;10(7):479–88.PubMedCrossRefGoogle Scholar
  8. 8.
    Nashkoev M, Sergeyev B. AIDS in the Commonwealth of Independent States, 2008 MAP report. 2008.Google Scholar
  9. 9.
    Renton A, Gzirishvilli D, Gotsadze G, Godinho J. Epidemics of HIV and sexually transmitted infections in Central Asia: trends, drivers and priorities for control. Int J Drug Policy. 2006;17(6):494–503.CrossRefGoogle Scholar
  10. 10.
    Favorov MO. HIV surveillance in countries of the Central Asian Republics. 2008.Google Scholar
  11. 11.
    Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–F65.PubMedCrossRefGoogle Scholar
  12. 12.
    Needle RH. Zhao L. HIV prevention among injection drug users: Strengthening U.S. support for core interventions; 2010.Google Scholar
  13. 13.
    Niccolai LM, Toussova OV, Verevochkin SV, Barbour R, Heimer R, Kozlov AP. High HIV prevalence, suboptimal HIV testing, and low knowledge of HIV-positive serostatus among injection drug users in St. Petersburg, Russia. AIDS Behav. 2010;14(4):932–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Chakrapani V, Newman P, Shunmugam M, Dubrow R. Social-structural contexts of needle and syringe sharing behaviours of HIV-positive injecting drug users in Manipur, India: a mixed methods investigation. Harm Reduct J. 2011;8(1):9.PubMedCrossRefGoogle Scholar
  16. 16.
    Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285.PubMedCrossRefGoogle Scholar
  17. 17.
    Strathdee SA, Lozada R, Martinez G, et al. Social and structural factors associated with HIV infection among female sex workers who inject drugs in the mexico-US border region. PLoS One. 2011;6(4):e19048.PubMedCrossRefGoogle Scholar
  18. 18.
    Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7(2):99–106.PubMedCrossRefGoogle Scholar
  19. 19.
    Auerbach JD, Parkhurst JO, Caceres CF. Addressing social drivers of HIV/AIDS for the long-term response: conceptual and methodological considerations. Global Public Health. 2011;6(suppl 3):S293–309.PubMedCrossRefGoogle Scholar
  20. 20.
    Epperson MW, Khan MR, Miller DP, Perron BE, El-Bassel N, Gilbert L. Assessing criminal justice involvement as an indicator of human immunodeficiency virus risk among women in methadone treatment. J Subst Abuse Treat. 2010;38(4):375–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Wechsberg WM, Parry CDH, Jewkes RK. Drugs, sex, gender-based violence, and the intersection of the HIV/AIDS epidemic with vulnerable women in South Africa. Policy Brief: RTI Press; 2010.CrossRefGoogle Scholar
  22. 22.
    Wechsberg WM, Luseno WK, Kline TL, Browne FA, Zule WA. Preliminary findings of an adapted evidence-based woman-focused HIV intervention on condom use and negotiation among at-risk women in Pretoria, South Africa. J Prevent Intervent Community. 2010;38(2):132–46.CrossRefGoogle Scholar
  23. 23.
    Finkelstein R, Netherland J, Sylla L, Gourevitch MN, Cajina A, Cheever L. Policy implications of integrating buprenorphine/naloxone treatment and HIV care. J Acquir Immune Defic Syndr. 2011;56:S98–104.PubMedCrossRefGoogle Scholar
  24. 24.
    Jablonowska E, Malolepsza E. Causes of antiretroviral therapy discontinuation in the outpatient HIV/AIDS clinic in Lodz. Przegl Epidemiol. 2010;64(4):491–5.PubMedGoogle Scholar
  25. 25.
    Tapp C, Milloy MJ, Kerr T, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. 2011;11:86.PubMedCrossRefGoogle Scholar
  26. 26.
    Boltaev AA, Deryabina AP, Kusainov A, Howard AA. Evaluation of a pilot medication-assisted therapy program in Kazakhstan: Successes, challenges, and opportunities for scaleup. Adv Prevent Med. 2012.Google Scholar
  27. 27.
    Booth RE, Mikulich-Gilbertson SK, Brewster JT, Salomonsen-Sautel S, Semerik O. Predictors of self-reported HIV infection among drug injectors in Kkraine. J Acquir Immune Defic Syndr. 2004;35(1):82.PubMedCrossRefGoogle Scholar
  28. 28.
    Young H, Moyes A, Seagar L, McMillan A. Novel recombinant-antigen enzyme immunoassay for serological diagnosis of syphilis. J Clin Microbiol. 1998;36(4):913.PubMedGoogle Scholar
  29. 29.
    El-Bassel N, Terlikbaeva A, Pinkham S. HIV and women who use drugs: double neglect, double risk. Lancet. 2010;376(9738):312.PubMedCrossRefGoogle Scholar
  30. 30.
    El-Bassel N, Remien RH. Couple-based HIV prevention and treatment: state of science, gaps, and future directions. In: Family and HIV/AIDS: Cultural and Contextual Issues in Prevention and Treatment. New York, NY: Springer; 2012. p. 153–172.Google Scholar
  31. 31.
    El-Bassel N, Wechsberg WM, Shaw SA. Dual HIV risk and vulnerabilities among women who use or inject drugs: no single prevention strategy is the answer. Curr Opin HIV AIDS. 2012;7(4):326–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83.PubMedCrossRefGoogle Scholar
  33. 33.
    Rhodes TJ, Donoghoe MC, Hunter GM, Stimson GV. Continued risk behaviour among HIV positive drug injectors in London: implications for intervention. Addiction. 1993;88(11):1553–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Nabila El-Bassel
    • 1
  • Louisa Gilbert
    • 1
  • Assel Terlikbayeva
    • 1
  • Elwin Wu
    • 1
  • Chris Beyrer
    • 2
  • Stacey Shaw
    • 1
  • Tim Hunt
    • 1
  • Xin Ma
    • 1
  • Mingway Chang
    • 1
  • Leyla Ismayilova
    • 3
  • Marat Tukeyev
    • 4
  • Baurzhan Zhussupov
    • 1
  • Yelena Rozental
    • 1
  1. 1.Global Health Research Center of Central AsiaColumbia UniversityNew YorkUSA
  2. 2.Center for Public Health and Human RightsJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  3. 3.School of Social Service AdministrationUniversity of ChicagoChicagoUSA
  4. 4.Kazakhstan National AIDS CenterAlmatyKazakhstan

Personalised recommendations